Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure.
Middlekauff
Holly R
HR
David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095, USA. hmiddlekauff@mednet.ucla.edu
D000222:Adaptation, Physiological; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002304:Cardiac Pacing, Artificial / Q000379:methods; D005081:Exercise Therapy / Q000379:methods; D017079:Exercise Tolerance / Q000502:physiology*; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D008297:Male; D009119:Muscle Contraction / Q000502:physiology; D018908:Muscle Weakness / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000503:physiopathology*; D009135:Muscular Diseases / Q000150:complications / Q000503:physiopathology* / Q000534:rehabilitation; D018384:Oxidative Stress / Q000502:physiology; D010101:Oxygen Consumption / Q000502:physiology*; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors; D013564:Sympathetic Nervous System / Q000502:physiology
D002118:Calcium